RIGImmune Announces Multiple Oral Presentations for Intranasal RIG-101 at European Respiratory Society Congress 2024 Pre-clinical studies for intranasal RIG-101, a first in class RIG-I agonist, demonstrate potent local innate immune stimulation and pan-viral activity against human rhinovirus, influenza and RSV...

RIGImmune Announces New Funding to Advance Development of RNA Virus Treatments Program-Related Investment and Grant from the Bill & Melinda Gates Foundation to advance RIGImmune’s RNA therapeutics platform for influenza and pan-viral respiratory therapies Company also...

RIGImmune Announces Acquisition of Antiviral Company Subintro and Concurrent Financing by F-Prime Capital FARMINGTON, Conn., Sept. 15, 2022 (GLOBE NEWSWIRE) -- RIGImmune Inc., a biopharmaceutical company developing a new class of RNA immunotherapeutics, today announced the acquisition of Subintro, a...